Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.
Phillip H. Kuo, MD, PhD
Advertisement
Articles by Phillip H. Kuo, MD, PhD
Phillip H. Kuo, MD, PhD, spoke about the future of theragnostic imaging in patients with metastatic castration-resistant prostate cancer.
Phillip H. Kuo, MD, PhD, spoke about how prostate-specific membrane antigen PET scan testing affected outcomes in patients with metastatic castration-resistant prostate cancer.
Phillip H. Kuo, MD, PhD, spoke about the use of theragnostic treatment and imaging for patients with metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
4
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
5
